Harue Tada

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02 (2009)

Nakagawa, Masatsugu, Nishimura, Tsutomu, Teramukai, Satoshi, Tada, Harue, Tanaka, Fumihiro, Yanagihara, Kazuhiro, ...

Abstract Background In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC). We...

Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma (2009)

Tada, Harue, Teramukai, Satoshi, Fukushima, Masanori, Sasaki, Hiroshi

Abstract Background Lymph node dissection has proven prognostic benefits for patients with ovarian or uterine carcinoma; however, one of the complications associated with this procedure is...

Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. (2006)

Nishimura, Tsutomu, Tada, Harue, Nakagawa, Masatsugu, Teramukai, Satoshi, Matsui, Shigeyuki

Objective: The objective of this study was to identify problems in the approval, pharmacovigilance, and post-approval regulatory decision-making procedures involving gefitinib and to propose...